A combined approach with rituximab plus anti-TRAIL-R Agonistic antibodies for the treatment of haematological malignancies

Current Pharmaceutical Design

Volumn 14, Issue 21, 2008, Pages 2085-2099

  Sancilio, Silvia ^a   Grill, Vittorio ^a   Di Pietro, Roberta ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Anti TRAIL R agonistic antibodies; Haematological malignancies; Rituximab; TRAIL; TRAIL receptors

Indexed keywords

CARBOPLATIN; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; GEMCITABINE; HGS ETR 1; HGS ETR 2; LEXATUMUMAB; MAPATUMUMAB; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NUTLIN 3; PACLITAXEL; PROTEIN KINASE B; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; TRITERPENOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; CANCER RESISTANCE; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; INNATE IMMUNITY; LEUKEMIA CELL; LIGAND BINDING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 52949147139     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785294582     Document Type: Review

References (163)

1. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nichol JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
3. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-60.
4. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973-82.
5. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-48.
6. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-2.
7. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
8. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-30.
9. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
10. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66.
11. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 2007; 85: 923-35.
12. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-40.
13. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
14. Voltz E, Gronemeyer H. A new era of cancer therapy: cancer cell targeted therapies are coming of age. Int J Biochem Cell Biol 2008; 40: 1-8.
15. Ozören N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135-47.
16. Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007; 39: 280-6.
17. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007; 224: 284-9.
18. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004; 103: 517-22.
19. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-40.
20. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005; 17: 610-6.
21. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-8.
22. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-21.
23. Greil R, Anether G, Johrer K, Tinhofer I. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J Leukoc Biol 2003; 74: 311-30.
24. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-20.
25. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000; 275: 25065-8.
26. Bodmer JL, Holler N, Reynard S. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-3.
27. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265-70.
28. Mühlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are nonredundant in JNK activation. J Biol Chem 2000; 275: 32208-13.
29. Wajant H, Moosmayer D, Wüest T, Bartke T, Gerlach E, Schïnherr U, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigendirected activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20: 4101-6.
30. Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective upregulation of TRAIL-R1. Blood 2001; 97: 2596-603.
31. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-3.
32. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20: 4601-12.
33. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395-403.
34. Coll-Mulet L, Iglesias-Serret D, Santidrián AF, Cosialls AM, de Frias M, Castano E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-14.
35. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007; 39: 568-77.
36. Thomas LR, Henson A, Reed JC, Salsbury FR, Thorburn A. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem 2004; 279: 32780-5.
37. Miyazaki T, Shen M, Fujikura D, Tosa N, Kim HR, Kon S, et al. Functional role of death-associated protein 3 (DAP3) in anoikis. J Biol Chem 2004; 279: 44667-72.
38. Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, et al. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 2008; 68: 909-17.
39. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-63.
40. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-53.
41. Leverkus M, Neumann M, Mengling T, Rauch CT, Bröcker EB, Krammer PH, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-9.
42. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-7.
43. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15: 42-8.
44. Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci 2007; 12: 3813-24.
45. Locklin RM, Croucher PI, Russell RG, Edwards CM. Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 2007; 21: 805-12.
46. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/ TRAIL. Curr Opin Pharmacol 2004; 4: 333-9.
47. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006; 84: 87-98.
48. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
49. Salvesen GS, Abrams JM. Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 2004; 23: 2774-84.
50. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000; 192: F21-5.
51. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22: 3842-52
52. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. PI-3K/ Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202: 900-11.
53. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 2006; 25: 7333-5.
54. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-21.
55. Jones RG, Elford AR, Parsons MJ, Wu L, Krawczyk CM, Yeh WC, et al. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 2002; 196: 335-48.
56. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, et al. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003; 86: 126-35.
57. Caravatta L, Sancilio S, di Giacomo V, Rana R, Cataldi A, Di Pietro R. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL. J Cell Physiol 2008; 214: 192-200.
58. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-83.
59. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 2003; 17: 379-89.
60. Kataoka K, Takikawa Y, Lin SD, Suzuki K. Prostaglandin E2 receptor EP4 agonist induces Bcl-xL and independently activates proliferation signals in mouse primary hepatocytes. J Gastroenterol 2005; 40: 610-6.
61. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-20.
62. Yang X, Thiele CJ. Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett 2003; 197: 137-43.
63. Mühlenbeck F, Haas E, Schwenzer R, Schubert G, Grell M, Smith C, et al. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998; 273: 33091-8.
64. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139: 89-97.
65. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-4.
66. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-76.
67. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-9.
68. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3.
69. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, et al. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med 1998; 4: 158-64.
70. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-803.
71. Paydas S, Tanriverdi K, Yavuz S, Disel U, Sahin B, Burgut R. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003; 14: 1045-50.
72. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002; 100: 2421-9.
73. Secchiero P, Milani D, Gonelli A, Melloni E, Zamai L, Celeghini C, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol 2003; 74: 223-32.
74. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997; 99: 618-24.
75. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 2001; 98: 2220-8.
76. Jones DT, Ganeshaguru K, Mitchell WA, Foroni L, Baker RJ, Prentice HG, et al. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol 2003; 121: 713-20.
77. Inukai T, Zhang X, Goto M, Hirose K, Uno K, Akahane K, et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006; 20: 2119-29.
78. Mullican SE, Zhang S, Konopleva M. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 2007; 13: 730-5.
79. Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 2007; 9: 853-61.
80. Tanaka H, Ito T, Kyo T, Kimura A. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007; 78: 389-98.
81. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D, et al. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci 2006; 1090: 209-16.
82. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98: 3058-65.
83. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002; 16: 67-73.
84. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 2003; 101: 3658-67.
85. Secchiero P, Vaccarezza M, Gonelli A, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004; 10: 3673-81.
86. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817-24.
87. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078-87.
88. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079-86.
89. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, et al. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 2000; 111: 580-6.
90. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002; 21: 6809-18.
91. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002; 29: 10-24.
92. Olsson A, Diaz T, Aguilar-Santelises M, Osterhorg A, Celsing F, Jondal M, et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001; 15: 1868-77.
93. Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 2005; 105: 3193-8.
94. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002; 100: 2965-72.
95. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 3584-92.
96. Cillessen SA, Meijer CJ, Ossenkoppele GJ, Castricum KC, Westra AH, Niesten P, et al. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. Br J Haematol 2006; 134: 283-93.
97. Blum A, Chaperot L, Molens JP, Foissaud V, Plantaz D, Plumas J. Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells. Exp Hematol 2006; 34: 1655-62.
98. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Dürkop, H, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 2007; 127: 2425-37.
99. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007; 178: 1923-30.
100. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175-93.
101. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
102. Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c3T3 cells. J Biol Chem 1995; 270: 13099-104.
103. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000; 27: 17-24.
104. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-74.
105. Tedder TF, Engel P. CD20: a regulator of cell cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-4.
106. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Expression of cell surface-markers after human B-lymphocte activation. Proc Natl Acad Sci USA 1981; 78: 3848-52.
107. Nobutaka O, Shinichi S, Tedder T. CD20 Workshop Panel Report. In: Kishimoto, T, eds. Leucocyte Typing VI. New York & London: Garland Publishing, Inc. 1997; 135-7.
108. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-43.
109. Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005; 72: 165-75.
110. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
111. Houghton AN, Scheinberg D. Monoclonal antibodies in the treatment of hematopoietic malignancies. Semin Hematol 1988; 25: 23-29.
112. LoBuglio A, Saleh M. Advances in monoclonal antibody therapy of cancer. Am J Med Sci 1992; 304: 214-24.
113. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 1992; 24: 524-6.
114. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1991; 90: 2188-95.
115. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333-50.
116. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
117. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982; 79: 7837-41.
118. Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005; 4: 7-14.
119. Li X, Wu L, Ying S, Chang C, He Q, Pu Q. Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. Leuk Lymphoma 2007; 48: 1353-71.
120. Rao AV, Schmader K. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. Am J Geriatr Pharmacother 2007; 5: 247-62.
121. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in Non-Hodgkin's lymphoma. Clin Cancer Res 2007; 13: 5636s-42s.
122. Plosker GL, Figgit DP. Rituximab: a review for its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-43.
123. Treon SP, Emmanouilides C, Kimby E, Kellier A, Preffer F, Brangan AR, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005; 16: 132-8.
124. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/ resistant follicular non-Hodgkin's lymphoma in patients both with land without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-301.
125. Kubota T, Moritani S, Yoshino T, Nagai H, Terasaki H. Ocular adnexal mucosa-associated lymphoid tissue lymphoma with polyclonal hypergammaglobulinemia. Am J Ophtalmol 2008; 145: 1002-6.
126. Tsirigotis P, Economopoulos T. Monoclonal antibodies in the treatment of lymphoid malignancies. J Steroid Biochem Mol Biol 2008; 108: 267-71.
127. Attias D, Weitsman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 2008; 20: 17-22.
128. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-407.
129. Marini P, Denzinger D, Schiller S, Kauder S, Welz R, Humphreys R, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006; 25: 5145-54.
130. Georgakis GV, Li Y, Humphreys R, Andrecff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130: 50-10.
131. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92: 1430-41.
132. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006; 28: 421-30.
133. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005; 11: 3126-35.
134. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hanson HJ, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007; 44: 1331-41.
135. Gong J, Yang D, Kohanim S, Humphreys R, Beoemeling L, Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptors agonist antibodies. Mol Cancer Ther 2006; 5: 2991-3000.
136. cip1-dependent decrease in surviving levels. Cancer Res 2007; 67: 6987-94.
137. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel PA. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mosothelionia and act synergistically with cisplatin. Mol Cancer 207; 6: 66-78.
138. Smith MR, Jin F, Joshi I. Bortezomib sensitizes Non-Hodgkin's Lymphoma cells to apoptosis induced,by antibodies to Tumor Necrosis Factor-related apoptosis-inducing Ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 2007; 13: 5528-34.
139. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; [Epub ahead of print] doi:10.1016/j.lungcan.2007.12.011.
140. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of Lexatumumab in patients with advanced cancer. Clin Cancer Res 2007; 13: 6187-94.
141. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23: 585-90.
142. Tolcher AW, Mita M, Merepol NJ, von Mcheren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. Clin Oncol 2007; 25: 1390-5.
143. Chow LQ, Eckhardt SG, Gustafson DL, O'Bryant C, Hariharan S, Diab S, et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignances: risults of a phase I and PK study. J Clin Oncol (ASCO Annu Meeting Proc) 2006; 24: 2515.
144. Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N, et al. HGS-ETR2 -a fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. J Clin Oncol (Annu Meeting Proc Part I) 2006; 24: 3012.
145. Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006; 5: 1844-53.
146. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haematopoetic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1998; 335: 440-2.
147. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Antibodies Targeting TRAIL-R1 and CD20. Clin Cancer Res 2007; 13: 4556-64.
148. Lee YJ, Chen JC, Amoscato AA, Bennouna J, Spitz DR, Suntharalingam M, et al. Protective role of Bcl2 in metabolic oxidative stress-induced cell death. J Cell Sci 2001; 114: 677-84.
149. Park SA, Park HJ, Lee BI, Ahn YH, Kim SU, Choi KS. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 2001; 93: 18-26.
150. Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signalling through the DR4 receptor by competing for ligand binding. J Biol Chem 2007; 38: 28189-94.
151. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic, interventions. Oncogene 2007; 26: 3629-36.
152. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-43.
153. Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110: 4037-46.
154. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6: 2644-52.
155. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab it patients with non-Hodgkin's lymphoma: increased interferon-α/β-inducible gene expression without significant toxicity, Blood 2005; 105: 489-95.
156. Zauli G, Secchiero P. The role of TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17: 245-57.
157. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998;91: 4624-31.
158. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, et al. TRAIL deficiency accelerates hematological malignancies. J Immunol 2005; 175: 5586-90.
159. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-61.
160. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199:437-48.
161. Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13(16): 1647-59.
162. Panteleev MA, Ananyeva NM, Ataullakhanov FI, Saenko EL, Mathematical models of blood coagulation and platelet adhesion: clinical applications. Curr Pharm Des 2007; 13(14):1457-67.
163. Yamazaki Y, Morita T. Snake venom components affecting blood coagulation and the vascular system: structural similarities and marked diversity. Curr Pharm Des 2007; 13(28): 2872-86.